322 related articles for article (PubMed ID: 31697814)
21. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.
Sano D; Liu N; Knowles S; MacEwan JP; Wang S; Wogen J; Yu KS; Lee ST
Curr Oncol; 2024 May; 31(5):2598-2609. PubMed ID: 38785476
[TBL] [Abstract][Full Text] [Related]
23. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ; Horwitz SM; Advani R; Christensen JH; Domingo-Domenech E; Rossi G; Morschhauser F; Alpdogan O; Suh C; Tobinai K; Shustov A; Trneny M; Yuen S; Zinzani PL; Trümper L; Ilidge T; O'Connor OA; Pro B; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Iyer S
Blood Adv; 2022 Oct; 6(19):5550-5555. PubMed ID: 35470385
[TBL] [Abstract][Full Text] [Related]
24. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
25. Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
Gentille C; Sarfraz H; Joshi J; Randhawa J; Shah S; Pingali SR
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1581. PubMed ID: 35263030
[TBL] [Abstract][Full Text] [Related]
26. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
27. Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.
Burke JM; Yu KS; Mordi U; Bloudek B; Liu N; Phillips T
J Manag Care Spec Pharm; 2023 Mar; 29(3):314-323. PubMed ID: 36840956
[No Abstract] [Full Text] [Related]
28. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
Oberic L; Delzor F; Protin C; Perriat S; Laurent C; Grand A; Canonge JM; Borel C; Gauthier M; Ysebaert L; Puisset F
J Oncol Pharm Pract; 2021 Oct; 27(7):1730-1735. PubMed ID: 33100177
[TBL] [Abstract][Full Text] [Related]
32. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas.
Karube K; Kakimoto Y; Tonozuka Y; Ohshima K
Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699
[TBL] [Abstract][Full Text] [Related]
33. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Calleja A; Bouclet F
Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
[No Abstract] [Full Text] [Related]
34. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
35. Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
[TBL] [Abstract][Full Text] [Related]
36. Update on the Treatment of Anaplastic Large Cell Lymphoma.
Vu K; Ai W
Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
40. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
